AU2008283989B2 - Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands. - Google Patents

Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands. Download PDF

Info

Publication number
AU2008283989B2
AU2008283989B2 AU2008283989A AU2008283989A AU2008283989B2 AU 2008283989 B2 AU2008283989 B2 AU 2008283989B2 AU 2008283989 A AU2008283989 A AU 2008283989A AU 2008283989 A AU2008283989 A AU 2008283989A AU 2008283989 B2 AU2008283989 B2 AU 2008283989B2
Authority
AU
Australia
Prior art keywords
escitalopram
treatment
disorder
serotonin reuptake
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008283989A
Other languages
English (en)
Other versions
AU2008283989A1 (en
Inventor
Nika Adham
Gary Samoriski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of AU2008283989A1 publication Critical patent/AU2008283989A1/en
Application granted granted Critical
Publication of AU2008283989B2 publication Critical patent/AU2008283989B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008283989A 2007-08-03 2008-08-04 Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands. Active AU2008283989B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95369407P 2007-08-03 2007-08-03
US60/953,694 2007-08-03
PCT/US2008/072066 WO2009020897A1 (en) 2007-08-03 2008-08-04 Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands

Publications (2)

Publication Number Publication Date
AU2008283989A1 AU2008283989A1 (en) 2009-02-12
AU2008283989B2 true AU2008283989B2 (en) 2013-12-05

Family

ID=40338740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008283989A Active AU2008283989B2 (en) 2007-08-03 2008-08-04 Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands.

Country Status (20)

Country Link
US (3) US20090036468A1 (cg-RX-API-DMAC7.html)
EP (1) EP2185155B1 (cg-RX-API-DMAC7.html)
JP (1) JP5460594B2 (cg-RX-API-DMAC7.html)
KR (1) KR101612563B1 (cg-RX-API-DMAC7.html)
CN (1) CN101815519B (cg-RX-API-DMAC7.html)
AU (1) AU2008283989B2 (cg-RX-API-DMAC7.html)
CA (1) CA2695519A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119828T1 (cg-RX-API-DMAC7.html)
DK (1) DK2185155T3 (cg-RX-API-DMAC7.html)
EA (1) EA018064B1 (cg-RX-API-DMAC7.html)
ES (1) ES2653852T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171908T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036004T2 (cg-RX-API-DMAC7.html)
LT (1) LT2185155T (cg-RX-API-DMAC7.html)
MY (1) MY157192A (cg-RX-API-DMAC7.html)
NO (1) NO2185155T3 (cg-RX-API-DMAC7.html)
PL (1) PL2185155T3 (cg-RX-API-DMAC7.html)
PT (1) PT2185155T (cg-RX-API-DMAC7.html)
SI (1) SI2185155T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009020897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101612146B1 (ko) 2008-07-16 2016-04-12 리히터 게데온 닐트. 도파민 수용체 리간드를 함유하는 약학적 제형
US20110117214A1 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
LT2582701T (lt) * 2010-06-18 2017-03-27 Altos Therapeutics, LLC D2 antagonistai, sintezės būdai ir panaudojimo būdai
WO2014031162A1 (en) 2012-08-20 2014-02-27 Forest Laboratories Holdings Limited Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HUP1700253A1 (hu) * 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
JP2024537491A (ja) * 2021-10-28 2024-10-10 アッヴィ・インコーポレイテッド 大うつ病性障害の治療
AU2022409230A1 (en) * 2021-12-13 2024-06-20 Compass Pathfinder Limited Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression
EP4493274A1 (en) * 2022-03-17 2025-01-22 Mapi Pharma Ltd. Depot systems comprising cariprazine or salts thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229297A1 (en) * 2003-08-04 2006-10-12 Richter Gedeon Vegyeszeti Gyar Rt. (THIO) Carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
WO2007124757A2 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Use of escitalopram for improving cognition
WO2008139235A2 (en) * 2007-05-11 2008-11-20 Richter Gedeon Nyrt. Novel piperazine salts as d3/d2 antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6556540B1 (en) * 1998-05-29 2003-04-29 Paradyne Corporation System and method for non-intrusive measurement of service quality in a communications network
PT1298124E (pt) * 1999-10-25 2007-05-31 Lundbeck & Co As H Método para a preparação de citalopram
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
CZ20033267A3 (en) * 2001-05-01 2004-06-16 H. Lundbeck A/S The use of enantiomeric pure escitalopram
WO2003086393A1 (en) * 2002-04-12 2003-10-23 Sepracor, Inc. 3-aza- and 1,4-diaza-bicyclo[4.3.0]nonanes, and methods of use thereof
KR20050012284A (ko) * 2002-06-20 2005-01-31 하. 룬트벡 아크티에 셀스카브 세로토닌 재흡수 저해제가 사용되는 병용 치료법
US20070042014A1 (en) * 2003-09-04 2007-02-22 H. Lundbeck A/S Combination of a serotonin reuptake inhibitor and loxapine
HUP0500170A3 (en) * 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229297A1 (en) * 2003-08-04 2006-10-12 Richter Gedeon Vegyeszeti Gyar Rt. (THIO) Carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
WO2007124757A2 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Use of escitalopram for improving cognition
WO2008139235A2 (en) * 2007-05-11 2008-11-20 Richter Gedeon Nyrt. Novel piperazine salts as d3/d2 antagonists

Also Published As

Publication number Publication date
CN101815519A (zh) 2010-08-25
EA201000280A1 (ru) 2010-08-30
HUE036004T2 (hu) 2018-06-28
HRP20171908T1 (hr) 2018-01-26
CN101815519B (zh) 2013-08-21
WO2009020897A1 (en) 2009-02-12
KR20100059830A (ko) 2010-06-04
EP2185155A1 (en) 2010-05-19
ES2653852T3 (es) 2018-02-09
KR101612563B1 (ko) 2016-04-14
EP2185155B1 (en) 2017-10-04
CA2695519A1 (en) 2009-02-12
US20120028991A1 (en) 2012-02-02
SI2185155T1 (en) 2018-02-28
NO2185155T3 (cg-RX-API-DMAC7.html) 2018-03-03
US20110015208A1 (en) 2011-01-20
JP5460594B2 (ja) 2014-04-02
HK1144784A1 (en) 2011-03-11
AU2008283989A1 (en) 2009-02-12
US20090036468A1 (en) 2009-02-05
JP2010535790A (ja) 2010-11-25
EA018064B1 (ru) 2013-05-30
DK2185155T3 (en) 2018-01-02
MY157192A (en) 2016-05-13
PL2185155T3 (pl) 2018-03-30
PT2185155T (pt) 2018-01-04
LT2185155T (lt) 2017-12-11
CY1119828T1 (el) 2018-06-27
EP2185155A4 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
AU2008283989B2 (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands.
KR20250029267A (ko) 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
CA2687528C (en) Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating acute mania
JP6668045B2 (ja) ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
US20120046302A1 (en) Methods of treating cns disorders
JP2025143406A (ja) 自閉症スペクトラム障害を治療するためのカルバモイルシクロヘキサン誘導体
RU2367440C2 (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
WO2010126527A1 (en) Methods of treating cns disorders
EP3156054A1 (en) Medicine for preventing and/or treating stress-induced diseases
US11547707B2 (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HK1144784B (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
US12263155B2 (en) Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
HK40067131A (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HK40067131B (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
OA20885A (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder.
JP2007512289A (ja) 不安処置のための（＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール
KR20100022956A (ko) 급성 조증 치료용 카르바모일-시클로헥산
HK1136984B (en) Carbamoyl-cyclohexanes for treating acute mania
HK40000275B (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)